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CardioprotectionMitochondria play a central role in heart energy metabolism and Ca2+ homeostasis and are involved in the
pathogenesis of many forms of heart disease. The body of knowledge on mitochondrial pathophysiology in
living cells and organs is increasing, and so is the interest in mitochondria as potential targets for
cardioprotection. This critical review will focus on the permeability transition pore (PTP) and its regulation by
cyclophilin (CyP) D as effectors of endogenous protective mechanisms and as potential drug targets. The
complexity of the regulatory interactions underlying control of mitochondrial function in vivo is beginning to
emerge, and although apparently contradictory ﬁndings still exist we believe that the network of regulatory
protein interactions involving the PTP and CyPs in physiology and pathology will increase our repertoire for
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Our current understanding of ischemia/reperfusion (I/R) injury is
greatly contributedby thenotion thatmitochondria are both apivotal site
for determining the loss of cell viability and a central target of processes
triggered by ischemia, such as elevation in intracellular Ca2+ and reactive
oxygen species (ROS). Therefore, it is not surprising that strategies aimed
at protecting against I/R damage have focused on mitochondria. During
the Seventies and Eighties major attention was given to metabolic
pathways, Ca2+ homeostasis and oxidative stress, yet mitochondrial
dysfunction as such was less studied. During the Nineties the number of
mitochondrial studies rose exponentially in almost every biomedicalﬁeld
mostly due to the recognized involvement of mitochondria in apoptosis,
which from the very beginning was linked to the mitochondrial
permeability transition pore (PTP) [1,2]. Concomitantly, the inhibition
of PTP opening by cyclosporine A (CsA) was shown to afford signiﬁcantcardioprotection against I/R injury [3,4]. At present, a general consensus
exists that the PTP is amajor factor indetermining cell death, and that PTP
inhibition affords signiﬁcant cardioprotection (reviewed in [5–7]), a
concept that has been successfully translated to clinical settings [8].
The PTP can be described as a voltage- and Ca2+-dependent, CsA-
sensitive, high-conductance channel located in the inner mitochon-
drial membrane (IMM) and regulated by the OMM through speciﬁc
protein–protein interactions [9,10]. Its opening causes a sudden
increase in IMM permeability (i.e., a permeability transition) to
solutes with molecular masses up to 1500 Da [11]. Surprisingly, the
molecular identity of the proteins responsible for this relevant
mitochondrial process has not been elucidated yet. Adenine nucleo-
tide translocase (ANT) and the voltage-dependent anion channel
(VDAC) have been proposed to represent PTP components, but
genetic studies have demonstrated that PTP opening can still be
observed in mitochondria devoid of these proteins, which therefore
might rather modulate PTP function [12].
2. PTP modulation and cyclophilin D
Factors involved in modulating the open probability of the PTP
have been analyzed in several reviews [5,11,13,14]. The long list of
PTP modulators includes ions and metabolites, lipids and components
of mitochondrial membranes, as well as soluble and membrane
proteins. Brieﬂy, PTP opening is favored by elevation in intramito-
chondrial [Ca2+] ([Ca2+]m), ROS, inorganic phosphate (Pi) and
mitochondrial depolarization. These factors are counteracted by
physiological PTP antagonists, such as elevated values of mitochon-
drial membrane potential (Δψm), pH values above or below the
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especially ADP.
The PTP is modulated also by the IMM surface potential
independently of changes in Δψm, consistent with the observations
that PTP opening is favored by polyanions and counteracted by
polycations [16]. Besides these modulators acting at the level of the
interface between phospholipid polar heads and the surrounding
aqueous milieu, also the hydrophobic core of the IMM appears to be
involved in PTP regulation. Indeed, heart mitochondria isolated from
rats fed with docosahexaenoic acid (DHA) display an increased DHA
content in mitochondrial phospholipids associated with a decreased
susceptibility to Ca2+-induced permeability transition [17].
Many proteins have been described to be involved in PTP
regulation, yet major attention has been focused on the matrix
protein cyclophilin (CyP) D due to its importance in pharmacological
control of PTP opening and to the pivotal information provided by its
genetic deletion (reviewed in [18]). PTP opening is facilitated by
binding of CyPD to the inner mitochondrial membrane (IMM) in a
process modulated by Ca2+, Pi and ROS [19]. Notably, CyPD binding to
the IMM is prevented by CsA and by other molecules interacting with
CyPD that are usually described as PTP inhibitors. However, since
increasing [Ca2+] results in PTP opening even in the presence of these
molecules, “PTP desensitization” describes better than “PTP inhibi-
tion” the effect of this family of compounds, a concept that also applies
to mitochondria devoid of CyPD [20]. It must be mentioned that PTP
desensitization by CsA or by CyPD ablation requires Pi, which under
these conditions behaves like a PTP inhibitor [19,21]. The evolutionary
implications of this ﬁnding have been discussed in a recent review
[22]. Recent work from the Halestrap laboratory has shown that the
polyclonal antibody used in previous studies to identify a CyPD-
binding protein of 32 kDa as ANT1 is rather labeling the Pi carrier,
which has now been incorporated in the model of the PTP proposed
by Halestrap's laboratory [23].
CyPD, the product of the Ppif gene, is a member of a family of
highly conserved peptidylprolyl cis-trans isomerases (PPIases or
rotamases, see below). Although this enzymatic activity relates
potentially all the CyPs to protein folding, the speciﬁc functions
played by the various members of this family are likely to depend
more on individual, speciﬁc structural determinants than on the
common denominator of rotamase activity [24]. Due to its unique N-
terminus CyPD is targeted to the mitochondrial matrix. Increased
intramitochondrial levels of Ca2+ and/or ROS promote a tight binding
of CyPD to the IMM in a process that is associated with PTP opening
and is antagonized by CsA. Although CsA inhibits the PPIase activity of
all CyPs, the enzymatic activity is not required for membrane binding
and stimulation of PTP opening [25]. The relationship between CyPD
and PTP has initially been demonstrated by pharmacology through
the use of CsA, and then corroborated by other CyPD ligands such as
sanglifehrin A, NIM-811, Debio-025 and antamanide [26–29]. How-
ever, conclusive evidence for a regulatory role of CyPD was provided
by genetic studies demonstrating that the propensity of the PTP to
open is reduced in mitochondria devoid of CyPD [20,30–32], while
susceptibility to PTP opening and to cell death is increasedwhen CyPD
is overexpressed [33,34], but see [35].
Recent observations indicate that CyPD can undergo covalent
modiﬁcations. In tumor cell models CyPD undergoes phosphorylation
on serine/threonine residues in a process that appears to be counter-
acted by extracellular signal regulated kinase (ERK) and promoted by
glycogen synthase kinase (GSK) 3 [36]. Consistent with this
hypothesis, a recombinant GSK3 could phosphorylate CyPD in vitro,
and an in silico analysis identiﬁed possible GSK3 target residues on
CyPD [36]. On the other hand, GSK3 inhibition results from its
phophorylation catalyzed by ERK. Notably, CyPD phosphorylation was
associated with an increased susceptibility to PTP opening. This link
between GSK3 and CyPD ﬁts the model proposed by Sollott and
coworkers concerning the role of the PTP in ischemic preconditioning(IPC) ([14], discussed below). However, besides the fact that at
present CyPD phosphorylation has not been documented in cardiac
myocytes, further studies are necessary to elucidate the mechanism
(s) whereby the (de)phosphorylation status of CyPD might control
PTP opening and its modulation by the other factors described above.
In addition, other CyPD sites could be phosphorylated by potentially
competing kinases resulting in a decreased probability of PTP opening,
or phosphorylation of PTP components could modulate the interac-
tion with CyPD. Thus, at this early stage PTP regulation by CyPD
phosphorylation should be regarded as an interesting possibility
rather than as an established fact.
Other covalent modiﬁcations of CyPD could be induced by ROS, and
redox changes have in fact beendescribed in CyPs fromdifferent species
[37–39]. Also human CyPD has been reported to display redox
regulation bymeans of thiol modiﬁcation [40]. Among its four cysteinyl
residues Cys203 oxidation has been shown to be especially relevant in
hampering isomerase activity. In addition, the formation of a disulﬁde
bond between Cys203 and Cys157 was shown to result in a signiﬁcant
conformational change [40]. However, no information is available on the
relationship between CyPD oxidation and PTP opening. Early studies
showed that treatment with oxidants promoted CyPD binding to the
inner mitochondrial membrane, and that the bound fraction was
enzymatically inactive [41]. Future studies on the link between
oxidative stress, CyPD and the PTP should also address the paradoxical
ﬁnding that a mild increase in ROS formation might be protective by
reducing PTPopening [42] as opposed to thewell-established damaging
effects induced by severe oxidative stress [41]. In this respect, and
depending on the amount of ROS, cysteinyl residues in CyPD might be
available for either inter- or intra-molecular disulﬁde cross-bridge
formation. The formation of intermolecular disulﬁde bridges might
promote CyPD aggregation or its covalent interaction with surrounding
proteins, which would in turn be prevented by generation of
intramolecular disulﬁde bonds.
3. Possible role of cyclophilin A
CyPs are ubiquitous proteins endowed with PPIase activity that
have been conserved during evolution [43,44]. They have been found
in the genomes of mammals, plants, insects, fungi and bacteria, and
share a common domain of approximately 109 amino acids, the CyP-
like domain [45]. In humans, cytosolic CyPA is the prototype of the
family and 16 unique CyPs have been found [43–45]. After binding
CsA, the PPIase activity is inhibited [46] and the CsA/CyPA complex
binds to and inhibits the cytosolic phosphatase calcineurin [47]
resulting in immunosuppression [48,49]. The PPIase activity of the
protein (or its inhibition) is not relevant for calcineurin inhibition
[50], suggesting that CyPs have speciﬁc cellular functions that may be
of importance for a variety of processes relevant to human disease
[45]. Speciﬁc functions are also suggested by the existence of tissue-
and organelle-speciﬁc isoforms characterized by the combination of
the signature CyP domain with the proper targeting and/or retention
sequence(s) [45]. Since all CyPs are inhibited by CsA and its analogs, a
role for isoforms other than CyPD in in vivo paradigms should always
be considered even when ligands that do not cause calcineurin
inhibition (like NIM811 and Debio 025) are used.
Cytosolic CyPA can be relevant to the cardioprotective effects of
CsA, which would add to those afforded by inhibition of CyPD. Indeed,
recent studies have revealed that translocation of the pro-ﬁssion
dynamin-related protein 1 (Drp1) to mitochondria (which favors
mitochondrial ﬁssion and thus fragmentation of the network)
requires its calcineurin-dependent dephosphorylation at Ser637
[51]. Since CsA in complex with cytosolic CyPA inhibits calcineurin
[47], CsA also affects mitochondrial shape and function independent
of its interactions with matrix CyPD, a fact that should be taken into
account when interpreting the effects of CsA on mitochondrial
function and cell survival [52]. The relevance of this problem is
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pharmacological inhibition of Drp1 affords a signiﬁcant protection
against cardiomyocyte injury caused by ceramide, hyperglycemia and
post-ischemic reperfusion [53–56]. In particular, upon treatment with
high glucose Drp1 translocation was shown to be responsible for an
increase in ROS formation that was followed by PTP opening [55].
Future studies will be necessary to clarify whether this sequence of
events can be translated from isolated cardiomyocytes exposed to an
extremely high glucose level to intact hearts in various pathological
conditions.
4. Additional mitochondrial effects of cyclophilin D
Recent work has identiﬁed interactions of CyPD with other
mitochondrial proteins that may be related to the PTP but could
also affect it indirectly through the modulation of PTP-regulatory
factors. One of the best characterized interactions is with the F1FO-ATP
synthase, which was recently documented in bovine heart mitochon-
dria [57]. Cross-linking studies demonstrated that CyPD forms a
complexwith the OSCP, b, and d subunits, i.e., that it interacts with the
extrinsic part of the lateral stalk [57]. CyPD binding was favored by Pi
and decreased the enzyme-speciﬁc activity, while CsA increased the
enzymatic activity and displaced CyPD from the ATP synthase.
Whether this striking analogy with Pi-dependent PTP regulation by
CyPD indicates a link between the two processes, or rather
modulation of the ATP synthase regulates the PTP through the matrix
levels of ADP, Pi and Mg2+ remains to be established.
CyPD interacts with a complex chaperone network involving
Hsp90 and its related molecule TRAP-1 [58]. CyPD bound to the
complex would no longer be available for PTP opening, and CyPD
displacement by selective Hsp90 antagonists like Shepherdin may
disrupt this protective network and activate the PTP with onset of cell
death. Given the prominence of the Hsp90–TRAP-1–CyPD interactions
in tumor cells, this strategy has been successfully used for their
selective killing [58]. A recent study also demonstrated a CsA-
sensitive interaction of CyPDwith Bcl2. CsA increased tBid-dependent
release of cytochrome c without PTP opening [59]. Consistent with
previous results [35], CyPD overexpression made cells more resistant
to apoptotic stimuli, a ﬁnding that is difﬁcult to reconcile with a
predominant effect of overexpression on the PTP [35,59]. This set of
studies suggests that CyPD overexpression may be a mechanism
through which tumor cells become resistant to death, and therefore
that CyPD inhibition might be an effective anti-cancer therapy.
5. PTP, cyclophilin D and cardioprotection
Although PTP structure is still elusive and its modulation is far
from having been conclusively elucidated, the relationship between
PTP opening and cell death is supported by a large body of evidence,
especially in the ﬁeld of acute myocardial ischemia and reperfusion.
PTP opening appears to be causally linked to the loss of cell viability as
demonstrated by the reduction in infarct size obtained when PTP
opening is counteracted by pharmacological inhibitors or by genetic
ablation of CyPD.
As detailed in several reviews [5,11,13,14], PTP opening favors ATP
depletion, deregulation of cellular Ca2+ homeostasis and oxidative
stress, all of which synergize in jeopardizing cell survival. The
sequence of events can be summarized as follows. PTP opening
determines an immediate collapse of Δψm that is followed by ATP
depletion. When opening is prolonged, the initial uncoupling-like
effect is rapidly followed by respiratory inhibition caused by loss of
pyridine nucleotides and of cytochrome c. This latter event can be
contributed by the rupture of the outer mitochondrial membrane
(OMM) that follows PTP-dependent matrix swelling, or by making
more cytochrome c available for release through cristae junction
widening followed by release through Bax/Bak channels through anotherwise intact OMM [60]. The resulting inhibition of electron ﬂow
might explain the increased ROS formation induced by PTP opening.
Since the latter event is favored by ROS [6,61], a vicious cycle of injury
ampliﬁcation is likely to be established, especially at the onset of
reperfusion.
Regarding ischemia/reperfusion injury, during ischemia the build-
up of factors favoring PTP opening (e.g., depolarization and increased
Ca2+ and Pi matrix levels) is balanced by the presence of PTP
antagonists (e.g., intracellular acidosis, high levels of Mg2+ and ADP),
which may prevail and prevent PTP opening. Conversely, upon
reperfusion the recovery of pH together with a burst in ROS formation
in the presence of high matrix concentrations of Ca2+ and Pi creates
optimal conditions for PTP opening in spite of the antagonizing effect
of Δψm recovery. The concept that PTP is more likely to open upon
reperfusion is supported by ﬁndings obtained in intact hearts using
direct methods for PTP assessment [4,62].
Decreased susceptibility to PTP opening appears also to be involved
in endogenous defense mechanisms that are triggered during ischemia
and reperfusion to maintain cardiomyocyte viability. Repeated short
episodes of ischemia and reperfusion protect from a subsequent
prolonged ischemia are a process termed “ischemic preconditioning”
(IPC) [63]. The deleterious effects of post-ischemic reperfusion have
been shown to be limited also by performing a series of very short
periods of ischemia and reperfusion at the time of reperfusion. This
maneuver is termed “ischemic post-conditioning” (IPoC), and has
received great attention as a protective strategy in the clinical setting
[64,65]. Both IPC and IPoC have been related to PTP [66–70] based upon
the following major lines of evidence: (i) IPC results in a decreased
occurrence of PTP opening during post-ischemic reperfusion [69,71];
(ii) IPC and IPoC reduce PTP susceptibility in mitochondria isolated
during reperfusion [66]; and (iii) cardioprotection by IPC and IPoC is
similar to that obtained using compounds (or interventions) that
decrease PTP opening [26,67], although from a theoretical standpoint
similar degrees of protection might result from completely different
mechanisms.
It has to be pointed out that the features of PTP opening in isolated
mitochondria are not necessarily reﬂecting the status of the pore in
situ, since conditions applied in the test tube are quite different from
those occurring in cardiomyocytes subjected to ischemia and
reperfusion. In addition, mitochondria extracted from protected
hearts are expected to perform better even if the PTP is not involved
in the protective mechanism in vivo.
The notion that the PTP contributes to mediate IPC has been
corroborated by observations suggesting that CyPD inhibition or
deletion abolishes the cardioprotective effects of IPC itself [72,73].
This apparent paradox reminds of, and ﬁts well with, the concept that
a slight increase in ROS formation during the preconditioning phase
prevents the large accumulation in ROS induced by reperfusion, and
thus results in maintenance of myocardial viability [74,75]. Indeed,
cardiomyocytes devoid of CyPD were shown to (i) lack the increase in
ROS formation that is otherwise induced by hypoxic preconditioning
and (ii) fail at activating Akt and Erk 1/2. In addition, hearts lacking
CyPD could not be further protected by IPC [72]. This interpretation
was put forward by Hausenloy et al., who proposed that IPC induces
transient, non-lethal opening of the PTP that protects from reperfu-
sion-induced prolonged opening. Although this hypothesis ﬁts our
demonstration that the PTP actually opens in intact cells under
“resting” conditions, as assessed with the calcein loading/cobalt
quenching technique [76], it might prove quite difﬁcult to assess in
intact hearts. For instance, under ischemic conditions intracellular pH
is likely to differ between isolated cardiomyocytes and intact hearts
and the same applies to pH recovery upon reperfusion. In addition, the
degree of protection elicited by CyPD deletion might already be
maximal, thus limiting the possibility of additional beneﬁt. Alterna-
tively, CyPD might be required for IPC-induced protection indepen-
dently of its role in PTP modulation (see above).
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function and structure, as well as PTP opening, have not yet been
elucidated. A large body of reports provided evidence of multiple
relationships between IPC/IPoC-induced changes in signaling path-
ways and the increased resistance of mitochondria to I/R injury
[14,77–81]. A comprehensive scheme has been proposed where IPC-
induced inactivation of GSK-3β is transduced to mitochondria
resulting in PTP inhibition [71]. The constitutively active GSK-3β
would be inactivated by phosphorylation at Ser9 catalyzed by
upstream protein kinases. These have been grouped under the
acronyms of RISK (Reperfusion Injury Salvage Kinase), including
phosphatidylinositol-3-OH kinase (PI3K)-Akt and Erk 1/2 [80], and
SAFE (Survivor Activating Factor Enhancement) describing the
activation of the cytokine tumor necrosis factor alpha (TNFα) and
signal transducer and activator of transcription-3 (STAT-3) [81]. In
addition, activation of cyclic GMP-dependent protein kinase (PKG)
[82], cyclic AMP-dependent protein kinase (PKA) [83] and PKCε [84]
has been reported to contribute to the maintenance of mitochondrial
function in hearts undergoing I/R, whereas PKCδ (together with GSK-
3β) appears to facilitate mitochondrial dysfunction [85].
Despite the large amount of data linking protein kinases with
mitochondrial (dys)function, how signaling pathways activated in the
cytosol might affect energy-linked process occurring within the IMM is
still far from being clear. Even assuming that signals are relayed or
proteins are translocated across the OMM to reach the intermembrane
space and/or innermitochondrial compartments, the (de)phosphorylated
proteins need to be deﬁned, and their causative role in PTP modulation
assessed. Candidate (de)phosphorylation reactionsmay involve theOMM
VDAC, thus affecting adenine nucleotide trafﬁc between mitochondria
and cytosol and/or binding of the antiapoptotic protein Bcl-2 [86]. A PTP-
regulatory role has been proposed also for IPC-induced opening of the
mitochondrial KATP channel (mitoKATP) by PKCε, whichmay cause a slight
increase in H2O2 formation eventually causing PTP inhibition [42]. The
ROS-mediated link between PKCε and mitoKATP involves additional
factors. For instance, the increase inROS formation inducedbydiazoxide is
blunted in cardiomyocytes and hearts of heterozygous connexin 43
deﬁcient (Cx43+/−) mice [87]. Therefore, it is tempting to speculate that
Cx43 favors PKCε interaction with mitoKATP or modulates directly
mitoKATP activity [88].
The possibility that PTP openingmight be prevented in response to
signaling pathways triggered by IPC or IPoC has been criticized
because susceptibility to PTP opening is not decreased in mitochon-
dria isolated at the end of the preconditioning phase, at variance from
what is observed at the onset of reperfusion [70]. Therefore, changes
occurring during ischemia rather than those produced during
preconditioning would be responsible for the IPC-induced resistance
to PTP opening. This criticism also matches the observation that in
some experimental models activation of the RISK pathway appears to
be independent of any protective effects [89,90]. It has been suggested
that rather than causing direct and immediate modiﬁcations in
protein (de)phosphorylation, IPC reduces the extent of oxidative
stress during ischemia and reperfusion [6,74]. Although the burst in
ROS formation occurring during reperfusion is clearly reduced in IPC-
treated cardiomyocytes [74], the mechanism by which IPC or IPoC
might affect oxidative stress is yet ill-deﬁned. Since ROS formation
and PTP opening are linked in a cycle, at present it cannot be
established whether reduced oxidative stress is upstream or down-
stream of decreased PTP opening. In addition, evidence that ischemia-
induced protein carbonylation is reduced in IPC-treated hearts [6]
does not help to clarify the underlying protective mechanisms.
Indeed, the carbonylated proteins inmitochondria were not identiﬁed
[6], and a major contribution might have come from contaminating
actin. Finally, oxidation of mitochondrial proteins is not necessarily
linked to adverse effects. For instance, oxidative modiﬁcation (i.e.,
nitrosylation) of Complex I has been suggested to be involved in IPC-
induced cardioprotection [91].6. The PTP as a Ca2+ release channel
Early work from our laboratories has indicated that in cultured cells
transient PTP openings take place under “resting” conditions [92], and
that PTP agonists induce cytochrome c release and cell death only for
prolonged PTP open times [76]. A physiological role was proposed for
these transient PTP openings, andwe have argued that the PTP could act
as a reversible fast Ca2+ release channel [93]. The advantage of an
unselective channel of high conductance would be to provide charge
compensation within the channel itself, thus allowing mitochondrial
Ca2+ release at zero potential, i.e., even for vanishingly small Ca2+
gradients [94]. This hypothesis is consistent with some early as well as
very recent observations related to heart mitochondria.
In 1992 Altschuld et al. showed that in isolated adult rat ventricular
cardiomyocytes the mitochondrial uptake of 45Ca2+ was doubled upon
treatment with CsA [95]. This rather overlooked ﬁnding has been
recently conﬁrmed and extended by a report showing that in
cardiomyocytes isolated from Ppif−/− mice the mitochondrial matrix
displays a 2.6-fold elevation in total Ca2+ levels as compared to wild
type littermates [96]. The matrix Ca2+ rise was shown to be linked to
activation of intramitochondrial Ca2+-dependent dehydrogenases
resulting in a stimulation of glucose oxidation at the expense of a
reduced fatty acid oxidation—a condition that resembles one of the
hallmarks of decompensated cardiac hypertrophy [97]. Perhaps even
more importantly, the absence of CyPD resulted in an increased
propensity for heart failure in three different models, i.e., transaortic
constriction, overexpression of Ca2+/calmodulin-dependent protein
kinase IIδc and swimming exercise [96]. The link with metabolic
changes might be not crucial, since the increased glucose oxidation
obtained by inhibiting pyruvate dehydrogenase kinase prevents
contractile derangements in two models of right ventricular hypertro-
phy [98]. Nevertheless, the study of Elrod et al. attributes a relevant role
to CyPD as a necessary factor for the physiological response of the heart
to mechanical stresses [96]. Apparently, this concept is disputed by
ﬁndings also reported by Molkentin's laboratory showing that CyPD
deletion prevented contractile impairment induced by overexpression
of sarcolemmal L-type Ca2+ channel [99]. However, in this latter model
CyPD protectionmight be ascribed to a reduced occurrence of cell death
caused by PTP opening following mitochondrial Ca2+ overload, a
condition that might not apply to other forms of heart failure. Thus, the
protection against cardiomyocyte necrosis afforded by CsA (or CyPD
ablation inmice) in experimental and clinicalmyocardial infarctionmay
comeat theprice of reducedmyocardial resistance to chronic conditions
of mechanical overload, that are possibly associated with an increased
susceptibility to apoptosis.
Recent work in mouse primary adult neurons also indicates that
PTP is only activated in response to the combined action of more than
one physiological stimulus affecting cytosolic Ca2+, and that under
these conditions PTP opening does not induce neuronal death but
rather takes part in cellular Ca2+ dynamics [100].
7. Conclusions
The role of the PTP and CyPs in cardioprotection is a rapidly
evolving area whose complexity is being increasingly appreciated. In
Fig. 1 we have summarized the potential beneﬁts and drawbacks of
PTP inhibition, which today is possible only through inhibition of
CyPD. We believe that the emerging network of regulatory protein
interactions involving the PTP and CyPs in physiology and pathology
will increase the repertoire of rationale therapeutic interventions in
heart disease.
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Fig. 1. Beneﬁcial and adverse effects induced by genetic deletion or pharmacological
inhibition of CyPD. Additional protection by CsA may derive from CyPA-dependent
inhibition of calcineurin, which prevents Drp1 dephosphorylation and mitochondrial
fragmentation. PN, pyridine nucleotides. For further explanation see text.
1320 F. Di Lisa et al. / Biochimica et Biophysica Acta 1813 (2011) 1316–1322References
[1] N. Zamzami, P. Marchetti, M. Castedo, D. Decaudin, A. Macho, T. Hirsch, S.A.
Susin, P.X. Petit, B. Mignotte, G. Kroemer, Sequential reduction of mitochondrial
transmembrane potential and generation of reactive oxygen species in early
programmed cell death, J. Exp. Med. 182 (1995) 367–377.
[2] P. Bernardi, V. Petronilli, F. Di Lisa, M. Forte, A mitochondrial perspective on cell
death, Trends Biochem. Sci. 26 (2001) 112–117.
[3] E.J. Grifﬁths, A.P. Halestrap, Protection by Cyclosporin A of ischemia/reperfusion-
induced damage in isolated rat hearts, J. Mol. Cell. Cardiol. 25 (1993) 1461–1469.
[4] E.J. Grifﬁths, A.P. Halestrap, Mitochondrial non-speciﬁc pores remain closed during
cardiac ischaemia, but open upon reperfusion, Biochem. J. 307 (1995) 93–98.
[5] F. Di Lisa, P. Bernardi, Mitochondria and ischemia–reperfusion injury of the
heart: ﬁxing a hole, Cardiovasc. Res. 70 (2006) 191–199.
[6] A.P. Halestrap, P. Pasdois, The role of the mitochondrial permeability transition
pore in heart disease, Biochim. Biophys. Acta (2009).
[7] C.P. Baines, The mitochondrial permeability transition pore and ischemia–
reperfusion injury, Basic Res. Cardiol. 104 (2009) 181–188.
[8] C. Piot, P. Croisille, P. Staat, H. Thibault, G. Rioufol, N. Mewton, R. Elbelghiti, T.T.
Cung, E. Bonnefoy, D. Angoulvant, C. Macia, F. Raczka, C. Sportouch, G. Gahide, G.
Finet, X. André-Fouët, D. Revel, G. Kirkorian, J.P. Monassier, G. Derumeaux, M.
Ovize, Effect of cyclosporine on reperfusion injury in acute myocardial infarction,
N. Engl. J. Med. 359 (2008) 473–481.
[9] R. Sinha Roy, M. Madesh, E. Davies, B. Antonsson, N. Danial, G. Hajnoczky, Bad
targets the permeability transition pore independent of Bax or Bak to switch
between Ca2+-dependent cell survival and death, Mol. Cell 33 (2009) 377–388.
[10] J. Sileikyte, V. Petronilli, A. Zulian, F. Dabbeni-Sala, G. Tognon, P. Nikolov, P.
Bernardi, F. Ricchelli, Regulation of the inner membrane mitochondrial
permeability transition by the outer membrane translocator protein (peripheral
benzodiazepine receptor), J. Biol. Chem. 286 (2011) 1046–1053.
[11] P. Bernardi, A. Krauskopf, E. Basso, V. Petronilli, E. Blalchy-Dyson, F. Di Lisa, M.A.
Forte, The mitochondrial permeability transition from in vitro artifact to disease
target, FEBS J. 273 (2006) 2077–2099.
[12] A. Rasola, P. Bernardi, The mitochondrial permeability transition pore and its
involvement in cell death and in disease pathogenesis, Apoptosis 12 (2007) 815–833.
[13] A.P. Halestrap, S.J. Clarke, S.A. Javadov, Mitochondrial permeability transition
pore opening during myocardial reperfusion—a target for cardioprotection,
Cardiovasc. Res. 61 (2004) 372–385.
[14] D.B. Zorov, M. Juhaszova, Y. Yaniv, H.B. Nuss, S. Wang, S.J. Sollott, Regulation and
pharmacology of the mitochondrial permeability transition pore, Cardiovasc.
Res. 83 (2009) 213–225.
[15] A. Nicolli, V. Petronilli, P. Bernardi, Modulation of the mitochondrial cyclosporin
A-sensitive permeability transition pore by matrix pH. Evidence that the pore
open-closed probability is regulated by reversible histidine protonation,
Biochemistry 32 (1993) 4461–4465.
[16] M.D. Linder, S. Morkunaite-Haimi, P.K. Kinnunen, P. Bernardi, O. Eriksson, Ligand-
selective modulation of the permeability transition pore by arginine modiﬁcation.Opposing effects of p-hydroxyphenylglyoxal and phenylglyoxal, J. Biol. Chem. 277
(2002) 937–942.
[17] K.M. O'Shea, R.J. Khairallah, G.C. Sparagna,W. Xu, P.A. Hecker, I. Robillard-Frayne,
R.C. Des, T. Kristian, R.C. Murphy, G. Fiskum, W.C. Stanley, Dietary omega-3 fatty
acids alter cardiac mitochondrial phospholipid composition and delay Ca2+-
induced permeability transition, J. Mol. Cell. Cardiol. 47 (2009) 819–827.
[18] V. Giorgio, M.E. Soriano, E. Basso, E. Bisetto, G. Lippe, M.A. Forte, P. Bernardi,
Cyclophilin D in mitochondrial pathophysiology, Biochim. Biophys. Acta 1797
(2010) 1113–1118.
[19] F. Di Lisa, P. Bernardi, A CaPful of mechanisms regulating the mitochondrial
permeability transition, J. Mol. Cell. Cardiol. 46 (2009) 775–780.
[20] E. Basso, L. Fante, J. Fowlkes, V. Petronilli, M.A. Forte, P. Bernardi, Properties of the
permeability transition pore in mitochondria devoid of Cyclophilin D, J. Biol.
Chem. 280 (2005) 18558–18561.
[21] E. Basso, V. Petronilli, M.A. Forte, P. Bernardi, Phosphate is essential for inhibition
of the mitochondrial permeability transition pore by cyclosporin A and by
cyclophilin D ablation, J. Biol. Chem. 283 (2008) 26307–26311.
[22] L. Azzolin, S. von Stockum, E. Basso, V. Petronilli, M.A. Forte, P. Bernardi, The
mitochondrial permeability transition from yeast to mammals, FEBS Lett. 584
(2010) 2504–2509.
[23] A.W. Leung, A.P. Halestrap, Recent progress in elucidating the molecular
mechanism of the mitochondrial permeability transition pore, Biochim. Biophys.
Acta 1777 (2008) 946–952.
[24] A. Galat, Peptidylproline cis-trans-isomerases: immunophilins, Eur. J. Biochem.
216 (1993) 689–707.
[25] L. Scorrano, A. Nicolli, E. Basso, V. Petronilli, P. Bernardi, Two modes of activation
of the permeability transition pore: the role of mitochondrial cyclophilin, Mol.
Cell. Biochem. 174 (1997) 181–184.
[26] L. Argaud, O. Gateau-Roesch, D. Muntean, L. Chalabreysse, J. Loufouat, D. Robert,
M. Ovize, Speciﬁc inhibition of the mitochondrial permeability transition
prevents lethal reperfusion injury, J. Mol. Cell. Cardiol. 38 (2005) 367–374.
[27] S.J. Clarke, G.P. McStay, A.P. Halestrap, Sanglifehrin A acts as a potent inhibitor of
the mitochondrial permeability transition and reperfusion injury of the heart by
binding to cyclophilin-D at a different site from cyclosporin A, J. Biol. Chem. 277
(2002) 34793–34799.
[28] L. Gomez, H. Thibault, A. Gharib, J.M. Dumont, G. Vuagniaux, P. Scalfaro, G.
Derumeaux, M. Ovize, Inhibition of mitochondrial permeability transition
improves functional recovery and reduces mortality following acute myocardial
infarction in mice, Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H1654–H1661.
[29] L. Azzolin, N. Antolini, A. Calderan, P. Ruzza, O. Marin, S. Mammi, P. Bernardi, A.
Rasola, Antamanide, a derivative of Amanita phalloides, is a novel desensitizer of
the mitochondrial permeability transition pore, Plos One in press (2010).
[30] C.P. Baines, R.A. Kaiser, N.H. Purcell, N.S. Blair, H. Osinska, M.A. Hambleton, E.W.
Brunskill, M.R. Sayen, R.A. Gottlieb, G.W. Dorn, J. Robbins, J.D. Molkentin, Loss of
cyclophilin D reveals a critical role for mitochondrial permeability transition in
cell death, Nature 434 (2005) 658–662.
[31] T. Nakagawa, S. Shimizu, T. Watanabe, O. Yamaguchi, K. Otsu, H. Yamagata, H.
Inohara, T. Kubo, Y. Tsujimoto, Cyclophilin D-dependent mitochondrial perme-
ability transition regulates some necrotic but not apoptotic cell death, Nature
434 (2005) 652–658.
[32] A.C. Schinzel, O. Takeuchi, Z. Huang, J.K. Fisher, Z. Zhou, J. Rubens, C. Hetz, N.N.
Danial, M.A. Moskowitz, S.J. Korsmeyer, Cyclophilin D is a component of
mitochondrial permeability transition and mediates neuronal cell death after
focal cerebral ischemia, Proc. Natl Acad. Sci. USA 102 (2005) 12005–12010.
[33] Y. Li, N. Johnson, M. Capano, M. Edwards, M. Crompton, Cyclophilin-D promotes
the mitochondrial permeability transition but has opposite effects on apoptosis
and necrosis, Biochem. J. 383 (2004) 101–109.
[34] J. Matas, N.T. Young, C. Bourcier-Lucas, A. Ascah, M. Marcil, C.F. Deschepper, Y.
Burelle, Increased expression and intramitochondrial translocation of cyclophilin-
D associates with increased vulnerability of the permeability transition pore to
stress-induced opening during compensated ventricular hypertrophy, J. Mol. Cell.
Cardiol. 46 (2009) 420–430.
[35] D.T. Lin, J.D. Lechleiter, Mitochondrial targeted cyclophilin D protects cells from cell
death by peptidyl prolyl isomerization, J. Biol. Chem. 277 (2002) 31134–31141.
[36] A. Rasola, M. Sciacovelli, F. Chiara, B. Pantic, W.S. Brusilow, P. Bernardi, Activation
of mitochondrial ERK protects cancer cells from death through inhibition of the
permeability transition, Proc. Natl Acad. Sci. USA 107 (2010) 726–731.
[37] K. Motohashi, F. Koyama, Y. Nakanishi, H. Ueoka-Nakanishi, T. Hisabori,
Chloroplast cyclophilin is a target protein of thioredoxin. Thiol modulation of
the peptidyl-prolyl cis-trans isomerase activity, J. Biol. Chem. 278 (2003)
31848–31852.
[38] P. Ghezzi, S. Casagrande, T. Massignan, M. Basso, E. Bellacchio, L. Mollica, E.
Biasini, R. Tonelli, I. Eberini, E. Gianazza, W.W. Dai, M. Fratelli, M. Salmona, B.
Sherry, V. Bonetto, Redox regulation of cyclophilin A by glutathionylation,
Proteomics 6 (2006) 817–825.
[39] L.J. Gourlay, F. Angelucci, P. Baiocco, G. Boumis, M. Brunori, A. Bellelli, A.E. Miele,
The three-dimensional structure of two redox states of cyclophilin A from
Schistosoma mansoni. Evidence for redox regulation of peptidyl-prolyl cis-trans
isomerase activity, J. Biol. Chem. 282 (2007) 24851–24857.
[40] D. Linard, A. Kandlbinder, H. Degand, P. Morsomme, K.J. Dietz, B. Knoops, Redox
characterization of human cyclophilin D: identiﬁcation of a new mammalian
mitochondrial redox sensor? Arch. Biochem. Biophys. 491 (2009) 39–45.
[41] C.P. Connern, A.P. Halestrap, Recruitment of mitochondrial cyclophilin to the
mitochondrial inner membrane under conditions of oxidative stress that
enhance the opening of a calcium-sensitive non-speciﬁc channel, Biochem. J.
302 (1994) 321–324.
1321F. Di Lisa et al. / Biochimica et Biophysica Acta 1813 (2011) 1316–1322[42] A.D. Costa, R. Jakob, C.L. Costa, K. Andrukhiv, I.C. West, K.D. Garlid, The mechanism
by which the mitochondrial ATP-sensitive K+ channel opening and H2O2 inhibit
the mitochondrial permeability transition, J. Biol. Chem. 281 (2006) 20801–20808.
[43] G. Fischer, B. Wittmann Liebold, K. Lang, T. Kiefhaber, F.X. Schmid, Cyclophilin
and peptidyl-prolyl cis-trans isomerase are probably identical proteins [see
comments], Nature 337 (1989) 476–478.
[44] N. Takahashi, T. Hayano, M. Suzuki, Peptidyl-prolyl cis-trans isomerase is the
cyclosporin A-binding protein cyclophilin, Nature 337 (1989) 473–475.
[45] P. Wang, J. Heitman, The cyclophilins, Genome Biol. 6 (2005) 226.
[46] J.F. Borel, C. Feurer, C. Magnee, H. Stahelin, Effects of the new anti-lymphocytic
peptide cyclosporin A in animals, Immunology 32 (1977) 1017–1025.
[47] J. Liu, J.D. Farmer Jr., W.S. Lane, J. Friedman, I. Weissman, S.L. Schreiber,
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506
complexes, Cell 66 (1991) 807–815.
[48] N.A. Clipstone, G.R. Crabtree, Identiﬁcation of calcineurin as a key signalling
enzyme in T- lymphocyte activation, Nature 357 (1992) 695–697.
[49] C.T. Walsh, L.D. Zydowsky, F.D. McKeon, Cyclosporin A, the cyclophilin class of
peptidylprolyl isomerases, and blockade of T cell signal transduction, J. Biol.
Chem. 267 (1992) 13115–13118.
[50] L.D. Zydowsky, F.A. Etzkorn, H.Y. Chang, S.B. Ferguson, L.A. Stolz, S.I. Ho, C.T.
Walsh, Active site mutants of human cyclophilin A separate peptidyl-prolyl
isomerase activity from cyclosporin A binding and calcineurin inhibition, Protein
Sci. 1 (1992) 1092–1099.
[51] G.M. Cereghetti, A. Stangherlin, B.O. Martins Test, Dephosphorylation by
calcineurin regulates translocation of Drp1 to mitochondria, Proc. Natl Acad.
Sci. USA 105 (2008) 15803–15808.
[52] M. Wasilewski, L. Scorrano, The changing shape of mitochondrial apoptosis,
Trends Endocrinol. Metab. 20 (2009) 287–294.
[53] V. Parra, V. Eisner, M. Chiong, A. Criollo, F. Moraga, A. Garcia, S. Hartel, E.
Jaimovich, A. Zorzano, C. Hidalgo, S. Lavandero, Changes in mitochondrial
dynamics during ceramide-induced cardiomyocyte early apoptosis, Cardiovasc.
Res. 77 (2008) 387–397.
[54] S.B. Ong, S. Subrayan, S.Y. Lim, D.M. Yellon, S.M. Davidson, D.J. Hausenloy,
Inhibiting mitochondrial ﬁssion protects the heart against ischemia/reperfusion
injury, Circulation 121 (2010) 2012–2022.
[55] T. Yu, S.S. Sheu, J.L. Robotham, Y. Yoon, Mitochondrial ﬁssion mediates high
glucose-induced cell death through elevated production of reactive oxygen
species, Cardiovasc. Res. 79 (2008) 341–351.
[56] J.X. Wang, J.Q. Jiao, Q. Li, B. Long, K. Wang, J.P. Liu, Y.R. Li, P.F. Li, miR-499
regulates mitochondrial dynamics by targeting calcineurin and dynamin-related
protein-1, Nat. Med. 17 (2011) 71–78.
[57] V. Giorgio, E. Bisetto, M.E. Soriano, F. Dabbeni-Sala, E. Basso, V. Petronilli, M.A.
Forte, P. Bernardi, G. Lippe, Cyclophilin D modulates mitochondrial F0F1-ATP
synthase by interacting with the lateral stalk of the complex, J. Biol. Chem. 284
(2009) 33982–33988.
[58] B.H. Kang, J. Plescia, T. Dohi, J. Rosa, S.J. Doxsey, D.C. Altieri, Regulation of tumor
cell mitochondrial homeostasis by an organelle-speciﬁc Hsp90 chaperone
network, Cell 131 (2007) 257–270.
[59] R.A. Eliseev, J. Malecki, T. Lester, Y. Zhang, J. Humphrey, T.E. Gunter, Cyclophilin D
interacts with Bcl2 and exerts an anti-apoptotic effect, J. Biol. Chem. 284 (2009)
9692–9699.
[60] L. Scorrano, M. Ashiya, K. Buttle, S. Weiler, S.A. Oakes, C.A. Mannella, S.J.
Korsmeyer, A distinct pathway remodels mitochondrial cristae and mobilizes
cytochrome c during apoptosis, Dev. Cell 2 (2002) 55–67.
[61] F. Di Lisa, N. Kaludercic, A. Carpi, R. Menabò, M. Giorgio, Mitochondrial pathways
for ROS formation and myocardial injury: the relevance of p66(Shc) and
monoamine oxidase, Basic Res. Cardiol. 104 (2009) 131–139.
[62] F. Di Lisa, R. Menabò, M. Canton, M. Barile, P. Bernardi, Opening of the
mitochondrial permeability transition pore causes depletion of mitochondrial
and cytosolic NAD+ and is a causative event in the death of myocytes in post-
ischemic reperfusion of the heart, J. Biol. Chem. 276 (2001) 2571–2575.
[63] E. Murphy, C. Steenbergen, Mechanisms underlying acute protection from
cardiac ischemia–reperfusion injury, Physiol. Rev. 88 (2008) 581–609.
[64] P. Staat, G. Rioufol, C. Piot, Y. Cottin, T.T. Cung, I. L'Huillier, J.F. Aupetit, E.
Bonnefoy, G. Finet, X. André-Fouët, M. Ovize, Postconditioning the human heart,
Circulation 112 (2005) 2143–2148.
[65] M. Ovize, G.F. Baxter, F. Di Lisa, P. Ferdinandy, D. Garcia-Dorado, D.J. Hausenloy,
G. Heusch, J. Vinten-Johansen, D.M. Yellon, R. Schulz, Postconditioning and
protection from reperfusion injury: where do we stand? Position paper from the
Working Group of Cellular Biology of the Heart of the European Society of
Cardiology, Cardiovasc. Res. 87 (2010) 406–423.
[66] L. Argaud, O. Gateau-Roesch, O. Raisky, J. Loufouat, D. Robert, M. Ovize,
Postconditioning inhibits mitochondrial permeability transition, Circulation
111 (2005) 194–197.
[67] D.J. Hausenloy, D.M. Yellon, S. Mani-Babu, M.R. Duchen, Preconditioning protects
by inhibiting the mitochondrial permeability transition, Am. J. Physiol. Heart
Circ. Physiol. 287 (2004) H841–H849.
[68] D.J. Hausenloy, D.M. Yellon, Preconditioning and postconditioning: united at
reperfusion, Pharmacol. Ther. 116 (2007) 173–191.
[69] S.A. Javadov, S. Clarke, M. Das, E.J. Grifﬁths, K.H. Lim, A.P. Halestrap, Ischaemic
preconditioning inhibits opening of mitochondrial permeability transition pores
in the reperfused rat heart, J. Physiol. 549 (2003) 513–524.
[70] A.P. Halestrap, S.J. Clarke, I. Khaliulin, The role of mitochondria in protection of
the heart by preconditioning, Biochim. Biophys. Acta 1767 (2007) 1007–1031.
[71] M. Juhaszova, D.B. Zorov, S.H. Kim, S. Pepe, Q. Fu, K.W. Fishbein, B.D. Ziman, S.
Wang, K. Ytrehus, C.L. Antos, E.N. Olson, S.J. Sollott, Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial
permeability transition pore, J. Clin. Invest. 113 (2004) 1535–1549.
[72] D.J. Hausenloy, S.Y. Lim, S.G. Ong, S.M. Davidson, D.M. Yellon, Mitochondrial
cyclophilin-D as a critical mediator of ischaemic preconditioning, Cardiovasc.
Res. (2010).
[73] D. Hausenloy, A. Wynne, M.R. Duchen, D. Yellon, Transient mitochondrial
permeability transition pore opening mediates preconditioning-induced pro-
tection, Circulation 109 (2004) 1714–1717.
[74] T.L. Vanden Hoek, L.B. Becker, Z. Shao, C. Li, P.T. Schumacker, Reactive oxygen
species released frommitochondria during brief hypoxia induce preconditioning
in cardiomyocytes, J. Biol. Chem. 273 (1998) 18092–18098.
[75] T. Pain, X.M. Yang, S.D. Critz, Y. Yue, A. Nakano, G.S. Liu, G. Heusch, M.V. Cohen, J.M.
Downey, Opening of mitochondrial K(ATP) channels triggers the preconditioned
state by generating free radicals, Circ. Res. 87 (2000) 460–466.
[76] V. Petronilli, D. Penzo, L. Scorrano, P. Bernardi, F. Di Lisa, The mitochondrial
permeability transition, release of cytochrome c and cell death. Correlation with
the duration of pore openings in situ. J. Biol. Chem. 276 (2001) 12030–12034.
[77] E. Murphy, C. Steenbergen, Preconditioning: the mitochondrial connection,
Annu. Rev. Physiol 69 (2007) 51–67.
[78] T. Miura, M. Tanno, T. Sato, Mitochondrial kinase signalling pathways in
myocardial protection from ischaemia/reperfusion-induced necrosis, Cardiovasc.
Res. 88 (2010) 7–15.
[79] D.J. Hausenloy, S. Lecour, D.M. Yellon, RISK and SAFE pro-survival signalling
pathways in ischaemic postconditioning: two sides of the same coin, Antioxid.
Redox Signal. (2010).
[80] D.J. Hausenloy, D.M. Yellon, New directions for protecting the heart against
ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase
(RISK)-pathway, Cardiovasc. Res. 61 (2004) 448–460.
[81] L. Lacerda, S. Somers, L.H. Opie, S. Lecour, Ischaemic postconditioning protects
against reperfusion injury via the SAFE pathway, Cardiovasc. Res. 84 (2009)
201–208.
[82] A.D. Costa, K.D. Garlid, I.C. West, T.M. Lincoln, J.M. Downey, M.V. Cohen, S.D.
Critz, Protein kinase G transmits the cardioprotective signal from cytosol to
mitochondria, Circ. Res. 97 (2005) 329–336.
[83] C. Perrino, A. Feliciello, G.G. Schiattarella, G. Esposito, R. Guerriero, L. Zaccaro, A.
Del Gatto, M. Saviano, C. Garbi, R. Carangi, L.E. Di, G. Donato, C. Indolﬁ, V.E.
Avvedimento, M. Chiariello, AKAP121 downregulation impairs protective cAMP
signals, promotes mitochondrial dysfunction, and increases oxidative stress,
Cardiovasc. Res. 88 (2010) 101–110.
[84] C.P. Baines, C.X. Song, Y.T. Zheng, G.W.Wang, J. Zhang, O.L.Wang, Y. Guo, R. Bolli, E.M.
Cardwell, P. Ping, Protein kinase Cepsilon interacts with and inhibits the permeability
transition pore in cardiac mitochondria, Circ. Res. 92 (2003) 873–880.
[85] E.N. Churchill, C.L. Murriel, C.H. Chen, D. Mochly-Rosen, L.I. Szweda, Reperfusion-
induced translocation of deltaPKC to cardiac mitochondria prevents pyruvate
dehydrogenase reactivation, Circ. Res. 97 (2005) 78–85.
[86] C. Steenbergen, S. Das, J. Su, R. Wong, E. Murphy, Cardioprotection and altered
mitochondrial adenine nucleotide transport, Basic Res. Cardiol. 104 (2009)
149–156.
[87] F.R. Heinzel, Y. Luo, X. Li, K. Boengler, A. Buechert, D. Garcia-Dorado, F. Di Lisa, R.
Schulz, G. Heusch, Impairment of diazoxide-induced formation of reactive
oxygen species and loss of cardioprotection in connexin 43 deﬁcient mice, Circ.
Res. 97 (2005) 583–586.
[88] D. Rottlaender, K. Boengler, M. Wolny, G. Michels, J. Endres-Becker, L.J. Motloch,
A. Schwaiger, A. Buechert, R. Schulz, G. Heusch, U.C. Hoppe, Connexin 43 acts as a
cytoprotective mediator of signal transduction by stimulating mitochondrial
KATP channels in mouse cardiomyocytes, J. Clin. Invest. 120 (2010) 1441–1453.
[89] S.J. Clarke, I. Khaliulin, M. Das, J.E. Parker, K.J. Heesom, A.P. Halestrap, Inhibition
of mitochondrial permeability transition pore opening by ischemic precondi-
tioning is probably mediated by reduction of oxidative stress rather than
mitochondrial protein phosphorylation, Circ. Res. 102 (2008) 1082–1090.
[90] A. Skyschally, P. van Caster, K. Boengler, P. Gres, J. Musiolik, D. Schilawa, R.
Schulz, G. Heusch, Ischemic postconditioning in pigs: no causal role for RISK
activation, Circ. Res. 104 (2009) 15–18.
[91] L.S. Burwell, S.M. Nadtochiy, A.J. Tompkins, S. Young, P.S. Brookes, Direct evidence
for S-nitrosation of mitochondrial complex I, Biochem. J. 394 (2006) 627–634.
[92] V. Petronilli, G. Miotto, M. Canton, M. Brini, R. Colonna, P. Bernardi, F. Di Lisa,
Transient and long-lasting openings of the mitochondrial permeability transi-
tion pore can be monitored directly in intact cells by changes in mitochondrial
calcein ﬂuorescence, Biophys. J. 76 (1999) 725–734.
[93] P. Bernardi, V. Petronilli, The permeability transition pore as a mitochondrial calcium
release channel: a critical appraisal, J. Bioenerg. Biomembr. 28 (1996) 131–138.
[94] P. Bernardi, Mitochondrial transport of cations: channels, exchangers, and
permeability transition, Physiol. Rev. 79 (1999) 1127–1155.
[95] R.A. Altschuld, C.M. Hohl, L.C. Castillo, A.A. Garleb, R.C. Starling, G.P. Brierley,
Cyclosporin inhibits mitochondrial calcium efﬂux in isolated adult rat ventric-
ular cardiomyocytes, Am. J. Physiol. 262 (1992) H1699–H1704.
[96] J.W. Elrod, R. Wong, S. Mishra, R.J. Vagnozzi, B. Sakthievel, S.A. Goonasekera, J.
Karch, S. Gabel, J. Farber, T. Force, J.H. Brown, E. Murphy, J.D. Molkentin,
Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange,
metabolic ﬂexibility, and propensity for heart failure in mice, J. Clin. Invest.
120 (2010) 3680–3687.
[97] J.J. Lehman, D.P. Kelly, Gene regulatory mechanisms governing energy
metabolism during cardiac hypertrophic growth, Heart Fail. Rev. 7 (2002)
175–185.
[98] L. Piao, Y.H. Fang, V.J. Cadete, C. Wietholt, D. Urboniene, P.T. Toth, G. Marsboom,
H.J. Zhang, I. Haber, J. Rehman, G.D. Lopaschuk, S.L. Archer, The inhibition of
1322 F. Di Lisa et al. / Biochimica et Biophysica Acta 1813 (2011) 1316–1322pyruvate dehydrogenase kinase improves impaired cardiac function and electrical
remodeling in two models of right ventricular hypertrophy: resuscitating the
hibernating right ventricle, J. Mol. Med. 88 (2010) 47–60.
[99] H. Nakayama, X. Chen, C.P. Baines, R. Klevitsky, X. Zhang, H. Zhang, N. Jaleel,
B.H. Chua, T.E. Hewett, J. Robbins, S.R. Houser, J.D. Molkentin, Ca2+- andmitochondrial-dependent cardiomyocyte necrosis as a primary mediator of
heart failure, J. Clin. Invest. 117 (2007) 2431–2444.
[100] A. Barsukova, A. Komarov, G. Hajnoczky, P. Bernardi, D. Bourdette,M. Forte, Activation
of the mitochondrial permeability transition pore modulates Ca2+ responses to
physiological stimuli in adult neurons, Eur. J. Neurosci. 33 (2011) 831–842.
